InDex Pharmaceuticals Holding AB (publ) interim report January-September 2023
InDex Pharmaceuticals discontinues cobitolimod phase III program”This surprising and disappointing news confirms the complexity of the disease and the need for further research within this field, especially as moderate to severe ulcerative colitis is an indication with high unmet medical need for new treatment options. We are incredibly grateful to all the patients, investigators and study personnel for their engagement to date. We will conduct a comprehensive analysis of all the study data before announcing next steps,” said Jenny Sundqvist, CEO of InDex Pharmaceuticals. Period July –